pSivida Corp. (NASDAQ: PSDV ), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has published final guidance indicating that ILUVIEN^® is not cost effective for the treatment of chronic diabetic macular edema (DME) considered